Fractyl Health Inc. (NASDAQ:GUTS) is one of the best young stocks with huge upside potential. On October 7, Fractyl Health ...

The new 12-month project extends a prior two-year award for which Habegger studied mechanisms of glucagon, Glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) and ...

Chugai Pharma concludes license agreement with Roche for CT-388, a long-acting GLP-1/GIP receptor agonist: Tokyo Saturday, October 11, 2025, 11:00 Hrs [IST] Chugai Pharmaceutical ...

Researchers say GLP-1 drugs prescribed for weight loss like Ozempic and Mounjaro are more effective at reducing heart health ...

On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes medications — also known as GLP-1 and GIP injections — are changing the way we ...

"Type 2 diabetes in children and teens is increasing at an alarming rate, yet treatment options are limited, and this patient population remains underserved," said Kenneth Custer, Ph.D., executive ...

Mounjaro, originally developed as a diabetes drug, has skyrocketed to become India’s no. 2 pharma brand, thanks to a booming ...

The excessive and uncontrolled consumption of alcohol, which can culminate in the development of alcohol use disorder or alcoholism, is widespread in many countries worldwide. Individuals diagnosed ...

BERLIN — A novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist combined into a single drug (LY3298176, Lilly), dubbed a "twincretin," ...

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor (single agonists such as semaglutide) and also dual glucose-dependent ...